1. Introduction {#sec1}
===============

Acute coronary syndrome (ACS), which includes ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina (UA), is a major cause of morbidity and mortality in the western world. The common denominator of ACS is a pathophysiologic process characterized by rupture of an atherosclerotic plaque, altered coronary vasomotor tone, platelet aggregation, and thrombosis. Compelling evidence from twin and epidemiological studies suggests a genetic basis underlying ACS \[[@B1], [@B2]\].

Histone deacetylases (HDACs) are a family of enzymes which balance the acetylating activities of histone acetyltransferases on chromatin remodeling and play essential roles in regulating gene transcription \[[@B3], [@B4]\]. About 18 mammalian HDACs have been identified and grouped into four classes based on their structural and biochemical characteristics \[[@B5]\]. HDAC9 is expressed in heart, T lymphocytes, endothelium, adipose tissues, vascular smooth muscle cells, and macrophages \[[@B5]--[@B7]\]. A recent genome-wide association study (GWAS) linked a variant of HDAC9 (rs11984041) on chromosome 7p21.1 with large-vessel ischemic stroke in individuals with European ancestry \[[@B8]\]. Han et al. reported that two SNPs, rs2389995 and rs2240419 on HDAC9, were significantly associated with large-vessel ischemic stroke risk in the Chinese population, although rs11984041 was not polymorphic in the Chinese population \[[@B9]\]. Upregulation of HDAC9 expression was observed in human atherosclerotic plaques including in carotid, aortic, and femoral plaques, which appears to implicate the altered HDAC9 expression in promoting atherosclerosis \[[@B6], [@B10]\]. Cao et al. showed that macrophage HDAC9 upregulation is atherogenic via suppression of cholesterol efflux and generation of alternatively activated macrophages in atherosclerosis \[[@B7]\]. Moreover, HDAC9 is also a common genetic variant that shares genetic susceptibility to ischemic stroke and coronary artery disease (CAD) \[[@B11]\].

In the present study, we aimed to examine the association between five SNPs of the HDAC9 gene and risk of ACS in a Chinese population. Our study represents one of the first efforts to associate risk alleles in HDAC9 gene region with ACS in the Chinese population.

2. Results {#sec2}
==========

2.1. Clinical Characteristics {#sec2.1}
-----------------------------

Baseline characteristics for all patients are shown in [Table 2](#tab2){ref-type="table"}. Proportion of males, number of smokers, incidence of diabetes, heart rate, fasting blood glucose, and hs-CRP were higher in ACS group as compared to those in the control group. Left ventricular ejection fraction (LVEF) and ApoA1 level were significantly lower in patients with ACS as compared to those in the controls. No other significant intergroup differences were observed.

2.2. Association of Allele and Genotypic Frequency Distribution with Susceptibility of ACS {#sec2.2}
------------------------------------------------------------------------------------------

Two SNPs, rs11984041 and rs2023938, were found to be nonpolymorphic in the Chinese population because rare five-T allele carrier of SNP rs11984041 and five-G allele carrier of SNP rs2023938 were found among both patients with ACS and controls. Genotype distributions for other three SNPs were in Hardy-Weinberg equilibrium in both groups (*P* \> 0.05, data not shown). [Table 3](#tab3){ref-type="table"} shows the association of HDAC9 gene alleles or genotypes with ACS.

We compared allele and genotype frequencies of the three SNPs between the two groups. We observed an association of rs2240419 with ACS risk, in which the A allele (*P* = 0.047) and the A allele carriers (AA + AG) (*P* = 0.037) were more frequent in ACS group, in contrast to those in the control group, whereas, none of the two other SNPs, rs2389995 and rs2107595, were significantly associated with ACS risk (*P* \> 0.05).

Multivariate logistic regression analysis of SNP rs2240419, adjusted for differences in age, sex, cigarette smoking, hypertension, diabetes, fasting blood glucose, hs-CRP, and lipoprotein variables, confirmed the independent association ([Table 4](#tab4){ref-type="table"}). A allele carriers in rs2240419 genotypes had an increased ACS risk as compared to that associated with the GG homozygotes; the adjusted OR was 1.869 (95% CI 1.143, 3.056,*P* = 0.013). Diabetes, smoking, and hs-CRP were the other variables that independently contributed to the risk of ACS, the adjusted ORs being 2.306 (95% CI 1.232, 4.317,*P* = 0.009) for diabetes, 3.909 (95% CI 2.142, 7.134,*P* \< 0.001) for smoking, and 1.126 (95% CI 1.043, 1.216,*P* = 0.002) for hs-CRP.

2.3. Relation between the rs2240419 Genotypes and Clinical Data {#sec2.3}
---------------------------------------------------------------

We also assessed the association of other clinical variables such as age, sex, cigarette smoking, hypertension, diabetes, fasting blood glucose, hs-CRP, and lipid profile, with rs2240419 genotypes ([Table 5](#tab5){ref-type="table"}). No significant intergroup differences were observed among genetic frequencies in rs2240419 with these clinical parameters.

3. Discussion {#sec3}
=============

In this study, we detected a significant correlation between rs2240419 polymorphism of HDAC9 gene and the susceptibility to ACS in a Chinese population, while the other four SNPs showed no such association.

A previous genome-wide association study (GWAS) demonstrated a significant association of SNP rs11984041 of HDAC9 gene with large-vessel stroke among populations of European ancestry \[[@B8]\]. Another GWAS on stroke in the European population revealed an association of polymorphic loci rs2107595 in HDAC9 gene susceptibility to large-vessel stroke \[[@B12]\]. Dichgans et al. evaluated the shared genetic determination of ischemic stroke and CAD and found that SNP rs2107595 on HDAC9 conferred susceptibility to both ischemic stroke and CAD among Caucasians \[[@B11]\]. Based on the HapMap data, SNP rs11984041 was found to be nonpolymorphic among the Chinese population. Our results are supported by two other studies which showed that SNP rs11984041 was not associated with stroke in a Chinese population, while two other SNPs, rs2389995 and rs2240419 of HDAC9, were significantly associated with large-vessel stroke risk \[[@B9], [@B13]\]. A recent study by Su et al. suggests that HDAC9 variant rs2107595 may not be associated with ischemic stroke risk in Chinese Han population \[[@B14]\]. Consistent with this study, we too found SNP rs11984041 to be nonpolymorphic in the Chinese population, and SNP rs2107595 was not significantly associated with ACS risk. This phenomenon may be attributed to genetic heterogeneity among different ethnic populations.

Eighteen HDACs are encoded by different genes and grouped into four classes on the basis of their structural and biochemical characteristics \[[@B15]\]. HDAC9 is a member of Class IIa HDACs. One of the best characterized mechanisms of action of HDAC9 is its ability to interact with MEF-2 and repress MEF-2 activity, which has been linked to suppression of cardiac hypertrophy \[[@B5], [@B16]\]. Moreover, HDAC9 expression was upregulated in human atherosclerotic plaques and was also a common genetic variant that shares the genetic susceptibility to ischemic stroke and coronary artery disease \[[@B11]\].

Cao et al. revealed the underlying molecular mechanisms of HDAC9 leading to increase of atherosclerosis in the in vivo models. HDAC9 deletion resulted in upregulation of lipid homeostatic genes, downregulation of inflammatory genes, and polarization of macrophages toward M2-like phenotype \[[@B7]\]. Recently another study found that HDAC9 regulates ox-LDL-induced endothelial cell apoptosis by participating in inflammatory reactions \[[@B17]\]. However, we did not observe a significant association between HDAC9 genetic variant and lipoproteins and inflammatory marker C-reactive protein. Thus, the mechanisms underlying the association of a mutant HDAC9 gene with ACS are still unknown.

4. Experimental Section {#sec4}
=======================

4.1. Subject Population {#sec4.1}
-----------------------

A total of 472 consecutive patients (309 patients with ACS and 163 patients with chest pain syndrome as controls) were admitted at the Department of Cardiology, the Second Affiliated Hospital of Medical College of Xi\'an Jiaotong University, between January 2012 and January 2015. All patients underwent elective coronary angiography because of the clinical indication. Two independent interventional cardiologists analyzed the coronary angiography results. The diagnosis of ACS was based on angiography, in accordance with the ACC/AHA guidelines. Subjects with chest pain syndrome were defined as having atypical chest pain without significant angiographic coronary stenosis, aortic dissection, and pulmonary embolism. Exclusion criteria included cancer, advanced liver or renal dysfunction, active inflammatory or autoimmune diseases, and hematological diseases. The research protocol was approved by the Ethics Committee at the Second Affiliated Hospital of Xi\'an Jiaotong University. Written informed consent was obtained from all the patients; the study complied with the principles enshrined in the Declaration of Helsinki. Demographic variables, cardiovascular risk factors, and past cardiovascular medical history were recorded for all patients.

4.2. Biochemical Analysis {#sec4.2}
-------------------------

Fasting blood glucose and serum concentrations of lipoproteins, apolipoproteins, and other biochemical parameters were measured in the clinical Biochemistry Department, at the Second Affiliated Hospital of the Medical College of Xi\'an Jiaotong University.

4.3. DNA Extraction and Genotyping {#sec4.3}
----------------------------------

Genomic DNA was extracted from peripheral blood lymphocytes (PBLs) using a commercial blood DNA extraction kit (Tiangen Biotech Co., Ltd., Beijing, China) following the manufacturer\'s protocol. Guided by the literature search, five SNPs in the HDAC9 gene variants were chosen for this study (SNP1 rs11984041, SNP2 rs2107595, SNP3 rs2023938, SNP4 rs2389995, and SNP5 rs2240419) \[[@B6], [@B8]--[@B11], [@B13], [@B14]\]. Genotyping for HDAC9 was performed using the ligation detection reaction (LDR) assay (Shanghai Biowing Applied Biotechnology Company) \[[@B18], [@B19]\]. All PCR primers and gene probes used in LDR were designed using Primer 3.0 and Oligo 6.0 software (listed in [Table 1](#tab1){ref-type="table"}). Each set of LDR probes is comprised of one common probe and two discriminating probes for the two types. DNA sequences of the HDAC9 gene were amplified by a multiplex polymerase chain reaction (PCR) method. All PCR reactions were carried out in a final volume of 20 *µ*L containing 2 *µ*L PCR buffer (1x), 3.0 mmol/L MgCl~2~, 2.0 mmol/L dNTP, 2 *µ*L primer mix, 0.2 *µ*L Taq Polymerase, and 1 *µ*L genomic DNA (50 ng/*µ*L). The amplification procedure was performed with an initial denaturation at 95°C for 2 min, followed by 40 cycles of denaturation at 94°C for 30 s, annealing at 53°C for 90 s, and extension at 65°C for 30 s, followed by a final extension at 65°C for 10 min in Gene Amp PCR system 9600 (Norwalk, CT, USA). The LDRs were performed in a final volume of 10 *µ*L containing 1 *µ*L buffer (1x), 1 *µ*L probe mix (2 pmol/*µ*L), 0.05 *µ*L Taq DNA ligase (NEB Biotechnology), and 4 *µ*L of multi-PCR product. The LDR included an initial incubation at 95°C for 2 min, followed by 40 cycles at 94°C for 15 s and 50°C for 25 s. The LDR fluorescent products were analyzed by ABI sequencer 3730. The quality of genotyping was controlled using blinded blood duplicates.

4.4. Statistical Analysis {#sec4.4}
-------------------------

All statistical analyses were conducted using SPSS software package, version 18.0 (SPSS Inc., Chicago, IL, USA). Quantitative variables are expressed as means ± Standard Error (SE) and categorical variables as frequency and percentage. Intergroup differences were assessed by Chi-square test or*t*-test. The genotype distributions for HDAC9 SNPs were tested for Hardy-Weinberg equilibrium. Owing to the small number of patients with AA homozygote in rs2240419 (*N* = 18 and *N* = 9 for ACS and control, resp.), AA and AG patients in rs2240419 were combined into a single A allele group (AA + AG) to improve the statistical power. The odds ratio (OR) and 95% confidence interval (95% CI) were calculated using binary logistic regression model to access associations between SNP rs2240419 and ACS risk. A 2-tailed*P* \< 0.05 was considered statistically significant.

5. Conclusion {#sec5}
=============

In this study, we demonstrated an association between rs2240419 polymorphism and risk of ACS in a Chinese population. Our findings also attest to the genetic heterogeneity between Chinese and other ethnic groups. However, several potential limitations of our study should be noted. Samples collected from a single center may not be sufficient and the chosen SNPs may not represent the entire HDAC9 gene. Future studies with larger sample size representative of the Chinese population are required to validate our findings.
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###### 

Primers and probes sequences (5′-3′) of HDAC9 SNPs for PCR and LDR.

  Primers and probes   Sequences (5′-3′)                                                                               Length                 
  -------------------- ----------------------------------------------------------------------------------------------- ---------------------- --------
  PCR primers                                                                                                                                  
   rs11984041          TTACTAGATCTGTCATGCAC                                                                            TGTGGTGGATGCACTGTATG   105 bp
   rs2389995           ACCCCAGAGAGAGTCCTCTA                                                                            CTGGATTAAAGAGTGCCAAC   94 bp
   rs2107595           GAAGGATGAGGAGCCATTAC                                                                            TTTGTGTGCTTGTACATTC    89 bp
   rs2023938           TCATTTCAACGGCTTCACAG                                                                            TGAGGGCCTTGACTATTTAG   118 bp
   rs2240419           CCACAGCTAAGAAGTATCAC                                                                            CCATGTTATGAAAAGCAGCC   101 bp
  Probes                                                                                                                                       
   rs11984041_modify   P-TGGCATCTCCATACAGTGCATCCACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-FAM                                  
   rs11984041_C        TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGAAGCTGGTAACTTCTACG                         150 bp                 
   rs11984041_T        TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGAAGCTGGTAACTTCTACA                       152 bp                 
   rs2389995_modify    P-GCCTTCTAAGGATCCAAGGAGAAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-FAM                                  
   rs2389995_A         TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAGAGAGAGTCCTCTAGCTCTCTTGTT                    155 bp                 
   rs2389995_G         TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAGAGAGAGTCCTCTAGCTCTCTTGTC                  157 bp                 
   rs2107595_modify    P-CAAAAAAGAATGTACAAGCACACAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-FAM                                  
   rs2107595_C         TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTACTGTGGGACAAAAACATTTTCCCG               160 bp                 
   rs2107595_T         TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTACTGTGGGACAAAAACATTTTCCCA             162 bp                 
   rs2023938_modify    P-TGCATTTTATTAACTGTGAAGCCGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-FAM                                  
   rs2023938_A         TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAGGTTAACACAGTTGTTTTGTCTGAT          165 bp                 
   rs2023938_G         TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAGGTTAACACAGTTGTTTTGTCTGAC        167 bp                 
   rs2240419_modify    P-AGATTGGTGCCAGTCTTGGTTGTGATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-FAM                                  
   rs2240419_A         TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGCAGCCCTGTGCACTGGTGAAGAGCT     170 bp                 
   rs2240419_G         TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGCAGCCCTGTGCACTGGTGAAGAGCC   172 bp                 

SNP, single nucleotide polymorphism; PCR, polymerase chain reaction; LDR, ligation detection reaction.

###### 

Clinical characteristics of subjects by study group.

  Characteristics    Control (*N* = 163)   ACS (*N* = 309)   *P*
  ------------------ --------------------- ----------------- ---------
  Sex (m/f)          94/69                 229/80            \<0.001
  Age (years)        59.66 ± 10.82         60.61 ± 11.98     0.401
  Hypertension (%)   54.6                  57.9              0.488
  Diabetes (%)       13.1                  25.2              0.002
  Smoking (%)        29.4                  55                \<0.001
  SBP (mmHg)         127.54 ± 22.74        127.74 ± 22.84    0.927
  DBP (mmHg)         78.82 ± 13.55         78.83 ± 13.89     0.998
  HR (bpm)           71.60 ± 14.64         74.72 ± 14.56     0.028
  LVEF (%)           63.45 ± 12.19         59.05 ± 12.16     \<0.001
  hs-CRP (mg/L)      2.23 ± 3.07           4.34 ± 4.26       \<0.001
  FBS (mmol/L)       5.88 ± 1.98           7.10 ± 3.43       \<0.001
  TC (mmol/L)        3.90 ± 0.91           3.85 ± 0.96       0.556
  TG (mmol/L)        1.60 ± 1.21           1.72 ± 1.18       0.302
  HDL-C (mmol/L)     0.98 ± 0.24           0.94 ± 0.63       0.484
  LDL-C (mmol/L)     2.32 ± 0.78           2.28 ± 0.85       0.617
  ApoA1 (g/L)        1.14 ± 0.21           1.07 ± 0.19       \<0.001
  ApoB (g/L)         0.76 ± 0.21           0.77 ± 0.22       0.752
  Statins (%)        83.4                  98.0              \<0.001
  ACEI/ARB (%)       69.9                  88.2              \<0.001
  *β*-blocker (%)    62.0                  86.6              \<0.001
  CCB (%)            24.5                  20.3              0.293

ACS, acute coronary syndrome; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; LVEF, left ventricular ejection fraction; hs-CRP, high sensitivity C-reactive protein; FBS, fasting blood sugar; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ACEI, angiotensin converting enzyme inhibition; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.

###### 

Genotypes and alleles distribution of HDAC9 gene SNPs in ACS and control.

               Control   ACS     *P*           
  ------------ --------- ------- ----- ------- ------------
  rs2389995                                     
   Genotypes                                    
    AA         113       69.30   198   64.10   0.377
    AG         45        27.60   104   33.70   
    GG         5         3.10    7     2.30    
   Allele                                       
    A          271       83.10   500   80.90   0.401
    G          55        16.90   118   19.10   
  rs2107595                                     
   Genotypes                                    
    CC         78        47.90   139   45.00   0.183
    CT         73        44.80   130   42.10   
    TT         12        7.40    40    12.90   
   Allele                                       
    C          229       70.20   408   66.00   0.188
    T          97        29.80   210   34.00   
  rs2240419                                     
   Genotypes                                    
    AA         9         5.50    18    5.80    0.037^*∗*^
    AG         48        29.40   127   41.10   
    GG         106       65.00   164   53.10   
   Allele                                       
    A          66        20.20   163   26.40   0.047^*∗*^
    G          260       79.80   455   73.60   

ACS, acute coronary syndrome; *∗* denotes *P* \< 0.05.

###### 

Results of logistic regression analysis showing risk factors for ACS.

  Covariates     Odds ratio (95% CI)    *P*
  -------------- ---------------------- ---------
  rs2240419      1.869 (1.143, 3.056)   0.013
  Sex            0.923 (0.516, 1.653)   0.788
  Age            1.018 (0.996, 1.040)   0.112
  Hypertension   1.334 (0.827, 2.152)   0.238
  Diabetes       2.306 (1.232, 4.317)   0.009
  Smoking        3.909 (2.142, 7.134)   \<0.001
  TC             1.646 (0.529, 5.124)   0.390
  TG             1.112 (0.886, 1.395)   0.360
  HDL-C          1.432 (0.556, 3.690)   0.457
  LDL-C          0.753 (0.226, 2.507)   0.644
  ApoA1 (g/L)    0.267 (0.035, 2.037)   0.203
  ApoB (g/L)     0.435 (0.028, 6.742)   0.552
  hs-CRP         1.126 (1.043, 1.216)   0.002

ACS, acute coronary syndrome; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B.

###### 

Association of rs2240419 genotypes and clinical characteristics.

  Covariates     AA + AG         GG              *P*
  -------------- --------------- --------------- -------
  Sex (m/f)      136/66          187/83          0.655
  Age            59.30 ± 11.40   61.01 ± 11.70   0.111
  Hypertension   55.9            57.4            0.750
  Diabetes       25.0            18.0            0.068
  Smoking        45.0            47.0            0.668
  TC             3.82 ± 0.88     3.90 ± 0.98     0.356
  TG             1.64 ± 1.01     1.71 ± 1.32     0.497
  HDL-C          0.91 ± 0.23     0.99 ± 0.67     0.158
  LDL-C          2.26 ± 0.79     2.32 ± 0.85     0.469
  ApoA1          1.08 ± 0.20     1.10 ± 0.21     0.354
  ApoB           0.75 ± 0.21     0.77 ± 0.22     0.424
  hs-CRP         4.03 ± 4.40     3.33 ± 3.72     0.091

TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B.
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